Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 9 studies | 37% ± 20% | |
neuron | 8 studies | 41% ± 20% | |
glutamatergic neuron | 6 studies | 42% ± 22% | |
interneuron | 6 studies | 36% ± 20% | |
oligodendrocyte precursor cell | 5 studies | 25% ± 6% | |
amacrine cell | 4 studies | 37% ± 19% | |
retinal ganglion cell | 4 studies | 63% ± 24% | |
retinal bipolar neuron | 3 studies | 25% ± 6% | |
GABAergic interneuron | 3 studies | 25% ± 5% | |
retina horizontal cell | 3 studies | 27% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 5804.91 | 2640 / 2642 | 99% | 216.17 | 695 / 705 |
adrenal gland | 99% | 1534.69 | 255 / 258 | 83% | 146.99 | 190 / 230 |
ovary | 87% | 994.56 | 156 / 180 | 85% | 73.67 | 367 / 430 |
prostate | 69% | 938.93 | 168 / 245 | 100% | 215.11 | 500 / 502 |
stomach | 77% | 981.95 | 275 / 359 | 83% | 78.06 | 237 / 286 |
skin | 58% | 486.51 | 1052 / 1809 | 85% | 100.53 | 403 / 472 |
breast | 55% | 547.95 | 251 / 459 | 86% | 83.11 | 957 / 1118 |
intestine | 37% | 331.80 | 361 / 966 | 90% | 84.56 | 472 / 527 |
pancreas | 41% | 296.79 | 135 / 328 | 67% | 45.41 | 120 / 178 |
uterus | 15% | 128.75 | 25 / 170 | 86% | 99.38 | 395 / 459 |
eye | 0% | 0 | 0 / 0 | 100% | 187.54 | 80 / 80 |
ureter | 0% | 0 | 0 / 0 | 100% | 112.46 | 1 / 1 |
thymus | 59% | 494.79 | 385 / 653 | 39% | 17.34 | 238 / 605 |
bladder | 14% | 101.00 | 3 / 21 | 78% | 81.58 | 392 / 504 |
kidney | 64% | 541.31 | 57 / 89 | 28% | 18.59 | 249 / 901 |
tonsil | 0% | 0 | 0 / 0 | 82% | 87.45 | 37 / 45 |
lung | 3% | 14.74 | 15 / 578 | 76% | 72.74 | 873 / 1155 |
esophagus | 11% | 70.88 | 158 / 1445 | 67% | 46.63 | 122 / 183 |
lymph node | 0% | 0 | 0 / 0 | 34% | 12.62 | 10 / 29 |
blood vessel | 20% | 128.94 | 266 / 1335 | 0% | 0 | 0 / 0 |
adipose | 19% | 122.57 | 231 / 1204 | 0% | 0 | 0 / 0 |
liver | 0% | 2.94 | 1 / 226 | 18% | 12.71 | 74 / 406 |
heart | 7% | 46.94 | 59 / 861 | 0% | 0 | 0 / 0 |
muscle | 2% | 14.53 | 20 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 2% | 16.55 | 21 / 929 | 0% | 0 | 0 / 0 |
spleen | 1% | 5.83 | 2 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050901 | Biological process | leukocyte tethering or rolling |
GO_0005796 | Cellular component | Golgi lumen |
GO_0005886 | Cellular component | plasma membrane |
GO_0005515 | Molecular function | protein binding |
GO_0005539 | Molecular function | glycosaminoglycan binding |
Gene name | PODXL2 |
Protein name | Podocalyxin-like protein 2 (Endoglycan) |
Synonyms | UNQ1861/PRO3742 |
Description | FUNCTION: Acts as a ligand for vascular selectins. Mediates rapid rolling of leukocytes over vascular surfaces through high affinity divalent cation-dependent interactions with E-, P- and L-selectins. . |
Accessions | Q9NZ53 ENST00000342480.7 [Q9NZ53-1] |